IMUC (EOM Pharmaceutical Holdings) Current Accrued Expense: $0.79 Mil (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is EOM Pharmaceutical Holdings Current Accrued Expense?

EOM Pharmaceutical Holdings IMUC Current Accrued Expense is $0.79 Mil as of Dec. 2022.

EOM Pharmaceutical Holdings's Current Accrued Expense for the quarter that ended in Dec. 2022 was $0.79 Mil.

EOM Pharmaceutical Holdings's quarterly Current Accrued Expense increased from Jun. 2022 ($ Mil) to Sep. 2022 ($0.69 Mil) and increased from Sep. 2022 ($0.69 Mil) to Dec. 2022 ($0.79 Mil).

EOM Pharmaceutical Holdings's annual Current Accrued Expense declined from Dec. 2023 ($1.03 Mil) to Dec. 2024 ($0.53 Mil) and declined from Dec. 2024 ($0.53 Mil) to Dec. 2025 ($ Mil).

EOM Pharmaceutical Holdings Current Accrued Expense Related Terms

EOM Pharmaceutical Holdings Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for EOM Pharmaceutical Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EOM Pharmaceutical Holdings Current Accrued Expense Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.79 1.03 0.53 -

EOM Pharmaceutical Holdings Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Mar21 Mar22 Jun22 Sep22 Dec22
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.68 - 0.69 0.79

EOM Pharmaceutical Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.79 Mil mean?
EOM Pharmaceutical Holdings (IMUC) has a Current Accrued Expense of $0.79 Mil as of Dec. 2022. Current Accrued Expense records the total amount of accrued expenses. View historical data on EOM Pharmaceutical Holdings and its competitors.
Is EOM Pharmaceutical Holdings' Current Accrued Expense too high?
EOM Pharmaceutical Holdings' current Current Accrued Expense is $0.79 Mil.
How does EOM Pharmaceutical Holdings' Current Accrued Expense compare to MNTMD and RTTR?
EOM Pharmaceutical Holdings' Current Accrued Expense of $0.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on EOM Pharmaceutical Holdings and its competitors. EOM Pharmaceutical Holdings's current Current Accrued Expense is $0.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EOM Pharmaceutical Holdings stock overvalued right now?
EOM Pharmaceutical Holdings (IMUC) has a current Current Accrued Expense of $0.79 Mil. The current Current Accrued Expense is $0.79 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For EOM Pharmaceutical Holdings (IMUC), the current Current Accrued Expense is $0.79 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EOM Pharmaceutical Holdings Business Description

Address 136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is a clinical-stage biotechnology company that is focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life in patients suffering from debilitating and sometimes deadly diseases. Its products have been approved in the U.S., rheumatoid arthritis, and inflammatory conditions of the gastrointestinal tract such as Crohn's Disease and Ulcerative Colitis as well as various retina disorders characterized by a breakdown of the blood-retinal barrier such as diabetic retinopathy, Aged related macular degeneration and retinal vein occlusion among others. Its pipeline includes its compound EOM613, an investigational novel dynamically dual-acting immunomodulator.